The effect of repurposing low-dose colchicine in older populations on platelet activation and inflammation (CO-OPERATE): A pilot trial.

Concord Hospital Cardiology Department0 个研究点目标入组 60 人开始时间: 2022年4月20日最近更新: 2024年4月8日

试验速览

暂无简介。

•People aged >= 70yrs not on medication or comorbidities affecting platelet function.
•Able to provide signed informed consent.
•Willingness to participate and comply with the study requirements.

•Medications and comorbidities affecting platelet function: on antiplatelet agent, anticoagulation, non steroid anti-inflammatory drugs (within 7 days), fish oil supplements (within 7 days), acute myocardial infarction, past cardiovascular disease, pulmonary embolism, active cancer, active sepsis or bleeding/clotting disorders.
•Definite indication for colchicine, such as acute gout or acute pericarditis
•Contraindication to colchicine, including:
•Hypersensitivity
•Currently taking or might need during the trial, a concomitant treatment which is contraindicated with colchicine: cyclosporin, strong CYP3A4 inhibitors, phenylbutazone, immunosuppressants and anti-neoplastic agents.
•Current/history of inflammatory bowel disease, chronic diarrhea, blood dyscrasias or eGFR<15mL/min/1.73m2.
•Current surgical or medical conditions that might significantly alter the absorption, distribution, metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection)
•History of alcohol or drug abuse within 12 months.
•Resident of aged care facility or significant cognitive impairment precluding consent

发起方

Concord Hospital Cardiology Department